Data demonstrate broad activity of CBX-12 across six tumor types with a strong response rate in TOP1-naïve patients with ...

NDAQ:SONN) Sonnet BioTherapeutics Completes Enrollment in Phase 1 Study of SON-1010 (IL12-FHAB) as a Monotherapy (SB101) for the Treatment of Solid Tumors ...

Additional Phase 2 studies in solid tumors are planned to begin in 2025.” CBX-12 is designed to deliver higher concentrations of exatecan, a topoisomerase 1 (TOP1) inhibitor, directly to tumor ...

The use of targeted therapy significantly improved ORR and PFS in patients with a long-term PFS benefit at one year and ...

Initial results from dose escalation in the first in-human phase 1 trial of DS-9606 suggest early promising clinical activity in patients with advanced solid tumours known to express Claudin-6 (CLDN6) ...

Carisma Therapeutics has gone public, entered a broad collaboration with Moderna, and ceased development of its original ...

Inavolisib showed promise in treating patients with PIK3CA-mutated solid tumors, demonstrating favorable safety and disease ...

Following an investigational new drug application clearance from the FDA, a phase 1 trial plans to evaluate CD-001.

In a recent study published in Nature Communications, researchers developed a microstructure-sensitive model to examine the ...

According to Biospace.com "The solid tumors market size reached a value of US$ 170.3 Billion in 2023. Looking forward, the market is expected to reach US$ 375.4 Billion by 2034, exhibiting a growth ...

AC Milan clinched three huge points and also broke their winning drought in the Derby della Madonnina against Inter on Sunday ...